The global healthcare specialty enzymes market size is anticipated to witness rapid growth during forecast period owing to its extensive usage in pharmaceutical industries. Enzymes have gained immense demand in diagnosis and clinical applications in the form of assays and techniques. For instance, enzyme linked immunosorbent assay (ELISA) makes use of peroxidase, alkaline phosphatase, and ß-galactosidase. Rising use of ELISA for diagnosis of noninfectious disease inclusive of hormones, drugs, serum components, and oncofetal proteins/autoimmune diseases.
Whereas, infectious disease diagnosis caused due to bacterial, viral, mycotic or parasitic organisms can be effectively diagnosed via ELISA technique. Enzyme multiplied immunoassay technique (EMIT) makes use of lysozyme and malate dehydrogenase. Analysis of glucose, uric acid, urea, and cholesterol content in blood is also done using the same.
Increase in the incidence of metabolic diseases associated with enzyme abnormality and incorporation of enzymes as disease markers across clinical examinations are contributing factors to the healthcare specialty enzymes market growth. In addition, specific locations of few enzymes in body tissues makes them a potent method of disease diagnosis. For instance, lactase dehydrogenase (LDH) is present in two different forms in skeletal muscle and heart; thus, changing dynamics of LDH in blood is expected to indicate onset of heart diseases.
Rapid shift from organic synthesis to diagnostic enzymatic applications in pharmaceutical industries has been observed in recent years. This is also supplemented by expansion of access to medical care in developing economies. Factors such as rising demand for preventive medicine, advent of DNA sequencing techniques, and momentum to molecular diagnostics is expected to boost the use of enzymatic diagnostic methods.
Alkaline phosphatases, creatine kinase, alanine aminotransferase, aspartate aminotransferase, sorbitol dehydrogenase (SDH), lactate dehydrogenases (LDH), cholinesterase (ChE), amylase, glutamyl transferase, trypsin, and glutathione peroxidases are incorporated in pathological diagnosis. In addition, these are potent alternatives for radioisotopes that are used in the form of markers in immunoassays. These are further used to identify diverse proteins and hormones.
Companies operating in global healthcare specialty enzymes market include Novozymes A/S, Codexis Inc., Affymetrix Inc., Advanced Enzymes Technologies Ltd., Amano Enzymes Inc., Biocatalysts Ltd., BBI Solutions, Roche CustomBiotech, Sekisui Diagnostics, Merck, F. Hoffmann-La Roche Ltd., Amano Enzymes, Inc. and Amicogen Inc. Regional companies largely investing in the development of specialty enzymes is expected to drive the growth of emerging markets.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.